Iqbal Hussain Sells 1,010 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 1,010 shares of the stock in a transaction on Friday, January 30th. The stock was sold at an average price of $25.01, for a total transaction of $25,260.10. Following the transaction, the insider owned 104,376 shares of the company’s stock, valued at $2,610,443.76. The trade was a 0.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ:CNTA opened at $25.00 on Thursday. The company’s 50-day moving average price is $25.32 and its two-hundred day moving average price is $22.62. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The stock has a market capitalization of $3.36 billion, a PE ratio of -13.66 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after purchasing an additional 979 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $218,000. DNB Asset Management AS bought a new position in Centessa Pharmaceuticals during the 3rd quarter worth $218,000. Finally, Sigma Planning Corp bought a new position in Centessa Pharmaceuticals during the 4th quarter worth $225,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CNTA shares. Guggenheim raised their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Wells Fargo & Company lifted their price objective on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Stephens initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.50.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.